

- **Name:** Hai-Qiang Mai
 - **Current Position & Affiliation:** Professor, PhD supervisor, Deputy Director of Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
 - **Country:** China
-

- **Educational Background:**

Dr. Mai graduated from Sun Yat-sen University of Medical Science in 1996, and then gained his MD and PhD degrees in Clinical Oncology in Sun Yat-sen Cancer Center. He worked as a postdoc in University of Florida Shands Cancer Center, USA from 2001 to 2002, and later completed clinical fellowship in the department of Clinical Oncology, the Hong Kong University.

- **Professional Experience:**

Dr. Mai is proficient in treating nasopharyngeal carcinoma, and his research is mainly focused on the prognosis and individualized treatment for nasopharyngeal carcinoma. As a principle investigator, Dr. Mai has been conducting multiple scientific researches since 2006, including the National Science Fund for Distinguished Young Scholars and the National Key Research and Development Program of China. Under his guidance, over 80 peer-reviewed papers are published in prestigious medical journals, such as Lancet Oncol, J Clin Oncol, J Natl Cancer Inst, Clin Cancer Res, etc.

Dr. Mai has won multiple First Prize of Science and Technology Development in China in recognition of his achievements. His other highlighted awards include Cancer Science Young Scientists Award (2006, Japan), Excellent Talents of the Ministry of Education in the New Century (2012), Leading Talents of Science and Technology Innovation in Guangdong Province (2015), Nobel Prize Star Award in 2015 Nobel Prize Laureates Summit, and Chinese Young Scientist Award in Oncology (2016), etc.

- **Professional Organizations:**

The Advisory Committee of MD Anderson Proton Therapy Center;
Chinese Anti-Cancer Association Youth Council;
Chinese Anti-Cancer Association, the Society of Nasopharyngeal Carcinoma;
Chinese Society of Clinical Oncology, Experts Committee on Nasopharyngeal Carcinoma;
Chinese Society of Biomedical Engineering, Precision Radiotherapy Technology;
Editorial Board Member in Cancer Communication.

• **Main Scientific Publications:**

1. Tang LQ, Chen DP, Guo L, Mo HY, Huang Y, Guo SS, Qi B, Tang QN, Wang P, Li XY, Li JB, Liu Q, Gao YH, Xie FY, Liu LT, Li Y, Liu SL, Xie HJ, Liang YJ, Sun XS, Yan JJ, Wu YS, Luo DH, Huang PY, Xiang YQ, Sun R, Chen MY, Lv X, Wang L, Xia WX, Zhao C, Cao KJ, Qian CN, Guo X, Hong MH, Nie ZQ, Chen QY, **Mai HQ***. 2018. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. *Lancet Oncol* 19: 461-73.
2. Tang LQ, Chen QY, Fan W, Liu H, Zhang L, Guo L, Luo DH, Huang PY, Zhang X, Lin XP, Mo YX, Liu LZ, Mo HY, Li J, Zou RH, Cao Y, Xiang YQ, Qiu F, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, **Mai HQ***. 2013. Prospective study of tailoring whole-body dual-modality [¹⁸F]fluorodeoxyglucose positron emission tomography/ computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. *J Clin Oncol* 31: 2861-9.
3. Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Zhang L, Guo SS, Liu LT, Guo L, Wu YS, Luo DH, Huang PY, Mo HY, Xiang YQ, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Cao KJ, Qian CN, Guo X, Zeng YX, **Mai HQ***, Zeng MS. 2016. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. *J Natl Cancer Inst* 108.
4. Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, **Mai HQ***. 2011. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. *J Natl Cancer Inst* 103: 1761-70.
5. Liu SL, Bian LJ, Liu ZX, Chen QY, Sun XS, Sun R, Luo DH, Li XY, Xiao BB, Yan JJ, Lu ZJ, Yan SM, Yuan L, Tang LQ*, **Mai HQ***. Development and Validation of the Immune signature to Predict Distant Metastasis in Patients with Nasopharyngeal Carcinoma. *Journal for Immuno Therapy of Cancer*, 2020.
6. Liu LT, Chen QY, Tang LQ, Guo SS, Guo L, Mo HY, Li Y, Tang QN, Sun XS, Liang YJ, Zhao C, Guo X, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J, **Mai HQ***. Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA. *Journal of the National Comprehensive Cancer Network*. 19;17(6):703–710.
7. Li XY, Chen QY, Sun XS, Liu SL, Yan JJ, Guo SS, Liu LT, Xie HJ, Tang QN, Liang YJ, Wen YF, Guo L, Mo HY, Chen MY, Sun Y, Ma J, Tang LQ*, **Mai HQ***. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. *European journal of cancer*. 2019; 110: 24-31.